On March 25, the Terumo production site of Leuven received an inspection of the Belgian Federal Agency for Medicines and Health Products (FAMHP). After a first analysis of the issue and based on the information they currently dispose of, the FAMHP advises patients not to suspend nor stop any treatments with Terumo injection needles.
“We have cooperated with FAMHP in full transparency during the inspection at our Leuven production site. We will continue to closely work with the authorities in the following weeks, as patient safety and the highest quality standards always come first at Terumo,” concludes Kyo Nishikawa, Managing Director Terumo Europe.
For more information on the FAMHP advice:• In Dutch: http://www.fagg-afmps.be/nl/news/news_terumo_2.jsp?referer=tcm:290-265076-64 • In French: http://www.fagg-afmps.be/fr/news/news_terumo_2.jsp?referer=tcm:291-265076-64
This is HCP only content